<DOC>
	<DOCNO>NCT00625313</DOCNO>
	<brief_summary>The purpose study assess safety efficacy HMY Model YA-60BB Intraocular Lens ( IOL ) implant posterior chamber human eye optical correction aphakia follow cataract extraction .</brief_summary>
	<brief_title>Clinical Study UV-Absorbing Acrylic Posterior Chamber Intraocular Lens</brief_title>
	<detailed_description>A prospective , single-phase , non-randomized , open-label study include patient operable cataract human crystalline lens potential post-operative best correct visual acuity 20/40 good pre-existing progressive sight-threatening ocular disorder . Patients eligible per inclusion / exclusion criterion undergo phacoemulsification cataract extraction implantation Hoya HMY Model YA-60BB posterior chamber intraocular lens . Each patient followed-up specific time interval assess safety effectiveness , 36 month .</detailed_description>
	<mesh_term>Aphakia</mesh_term>
	<criteria>1 . Adult patient cataract eligible phacoemulsification cataract extraction lens incision approximately 4 mm , primary implantation posterior chamber intraocular lens . 2 . Patients must preexist ocular condition preclude ability treat eye achieve BCVA 20/40 good IOL implantation . 3 . Patients must least 21 year age . 4 . Patients must sign write informed consent form . 5 . Patients must able willing return schedule followup examination surgery throughout 36 month study . 1 . Patients history of/or clinical sign follow sightthreatening condition : 1 . Previous Retinal Detachment retinal pathology operative eye , 2 . Macular Degeneration either eye 3 . Macular Edema either eye 4 . Persistent Iritis/Uveitis operative eye , 2 . Uncontrolled Glaucoma current treatment glaucoma either eye 3 . Significant Corneal Disease operative eye , 4 . Proliferative Diabetic Retinopathy either eye 5 . Patients previous ocular surgery , kind , within last 6 month patient previous ocular surgery time potential BCVA cataract extraction/IOL implantation 20/40 good 6 . Patients best correct vision worse 20/200 fellow eye . 7 . Patients serious ( i.e. , life threaten ) nonophthalmic disease may preclude study completion . 8 . Patients undergone previous cataract extraction intraocular lens implantation . 9 . Patients unwilling unable sign IRBapproved inform consent document study complete study 's examination schedule . 10 . Patients currently enrol another clinical trial , exit clinical trial within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Cataract</keyword>
	<keyword>aphakia</keyword>
	<keyword>intraocular lens</keyword>
	<keyword>IOL</keyword>
	<keyword>Optical correction aphakia</keyword>
</DOC>